MYH9 and neuroblastoma: Meanwhile, the expression of MYH9, FN1, LTBP1, CALR and AKAP12 is effective in discriminating HR-NB from LR-NB patients, indicating that these non-invasive biomarkers may be used to detect patients at risk of developing aggressive tumor phenotypes.